HENAFENTRINE

This brand name is authorized in Nigeria.

Active ingredients

The drug HENAFENTRINE contains a combination of these active pharmaceutical ingredients (APIs):

1	Artemether UNII C7D6T3H22J - ARTEMETHER
	Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
	Read more about Artemether
2	Lumefantrine UNII F38R0JR742 - LUMEFANTRINE
	Read more about Lumefantrine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A11-100618	Tablet	HENAFENTRINE 20/120 Tablets TAB 20 mg; 120 mg 1 x 24 tablets	73 NF-PP-339366 HENAFENTRINE 20/120 Tablets Artemether 20 mg and Lumefantrine 120 mg Tablets Each uncoated Tablet contains Artemether 20 mg Lumefantrine 120 mg MCCP 101 BP 63.55 mg Cross Carmellose Sodium BP 4.50 mg IPA BP QS Sodium Benzoate BP 2.20 mg PVPK30 BP 11 mg Colloidal Silicone Dioxide BP 5.50 mg Magnesium Stearate BP 4.50 mg Lactose BP 98.65 mg Talcum BP 6.50 mg Sodium Starch Glycolate BP 13.60 mg A11-100618 Drugs Nigerian Products 124tabs OTC 6/26/2023 SAGAR VITACEUTICALS NIGERIA LTD., PLOT 2, LADIPO OLUWOLE STREET 9022977711 suptpharm@svnl.in Sagar Vitaceuticals Nigeria Limited, Plot 2, Ladipo Oluwole Street, Off Oba Akran Avenue, Ikeja, Lagos, Nigeria, Nigeria	21/12/2023
A11-1189	Tablet	Henafentrine Tablets TAB 80 mg; 480 mg		01/09/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01BF01	Artemether and lumefantrine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A11-100618, A11-1189